[Hiring] Associate Director, Clinical Science @Braveheart Bio

Role Description

The Associate Director, Clinical Science will serve as a key scientific contributor within Braveheart Bio's Clinical Development organization, partnering closely with the Clinical Development Medical Directors to shape and execute the clinical and translational science strategy for BHB-1893 across the hypertrophic cardiomyopathy spectrum (oHCM and nHCM).

This role will play a critical part in preparing BHB-1893 for global Phase 3 execution and regulatory submissions. The Associate Director, Clinical Science will provide scientific leadership for:

• Protocol design and endpoint strategy
• Clinical data review and quality
• Independent analysis of clinical, biomarker, and exploratory endpoint data
• The scientific content of clinical study reports, publications, and regulatory documents

Working cross-functionally with Biometrics, Clinical Pharmacology, Data Management, and Clinical Operations, this individual will translate complex datasets into clear scientific insights that inform program decisions, drawing on sarcomere biology and disease-specific pharmacodynamic considerations.

The role will also serve as a key clinical science point of contact for Braveheart's global co-development partnership, working closely with the partner team to support:

• Clinical data review, cleaning, and reconciliation
• Ensure consistent scientific interpretation of data across global development programs

In addition, the Associate Director, Clinical Science will help represent the science of BHB-1893 externally with key opinion leaders, advisory boards, and the broader cardiovascular scientific community.

Qualifications

• PhD or equivalent research doctorate (field flexible); other advanced degrees (e.g., PharmD, MS with substantial relevant experience) will be considered
• 6+ years of experience in clinical development and/or translational research
• Demonstrated experience conducting hands-on review and quality control of clinical data listings
• Experience collaborating with co-development partners, CROs, or other external organizations on clinical data review, cleaning, and reconciliation, ideally in global Phase 3 trials through database lock
• Strong independent data analysis skills, including the ability to identify patterns, anomalies, and scientific signals in complex clinical datasets
• Working knowledge of cardiovascular disease biology, ideally including sarcomere biology and hypertrophic cardiomyopathy
• Experience authoring or contributing to clinical study protocols, clinical study reports, and regulatory documents (e.g. NDA/MAA submissions)
• Strong interpersonal and communication skills for bridging between scientific and business participants, for negotiating timelines and for effective international collaboration
• Strong written and verbal communication skills with a collaborative, team-oriented approach
• Ability to thrive in a fast-paced, dynamic environment and remain comfortable with change and ambiguity
• Flexible, proactive, and hands-on mindset with a roll-up-your-sleeves, can-do attitude

Requirements

• Programming experience (e.g., R, Python, or SAS) sufficient to analyze clinical datasets
• Track record of developing novel analytic approaches to complex biomarker or clinical trial data
• Experience engaging with KOLs, scientific advisory boards, or presenting at cardiovascular conferences (e.g., ESC, AHA, HFSA)
• Fluency in Mandarin

Benefits

• Base Salary Range: $180,000 - $240,000
• Eligible for a competitive total rewards package, which may include an annual bonus, equity, and a comprehensive benefits offering

Company Description

Braveheart Bio is a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. Our lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor (CMI) being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM).

Braveheart’s goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, reversibility and reducing prescribing complexity.

With a proven leadership team, a strong financial foundation, and a high-value late-stage asset, Braveheart Bio represents an outstanding opportunity for ambitious, mission-driven professionals to make a tangible impact in a high-profile and rapidly evolving therapeutic area.